Here, we demonstrate in a proof-of-principle study that low dose metronomic TPT does not elicit a tumor-promoting, but rather tumor-inhibiting senescence phenotype due to a lack of NFKB1/p50 activation and leads to tumor remission in an animal model for the MYCN amplified, aggressive childhood cancer neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.